Dublin, April 28, 2025 (GLOBE NEWSWIRE) -- The "U.S. Meal Replacements Market 2025: Retail & Multi-Level Channels" report from Marketdata LLC has been added to ResearchAndMarkets.com's offering.
The U.S. meal replacements market, valued at $5.1 billion, has shown resilience over the past few years despite facing strong competition from GLP-1 drugs. Although these medications have impacted market share, particularly affecting companies like Medifast, projections indicate growth in 2025 and 2028.
Meal replacement shakes and nutrition bars continue to be favored for DIY weight loss, thanks to their accessibility, cost-effectiveness, and lack of side effects.
During 2023-2024, companies in the meal replacements niche saw a substantial $1.5 billion loss to the GLP-1 drugs market. Notably, Medifast experienced a significant decline. In response, some competitors have strategically incorporated GLP-1 drugs into their programs to adapt and secure future positioning. Additionally, high-protein meal replacements are being marketed as complementary products to weight loss drugs, aligning with evolving consumer preferences.
The comprehensive Marketdata report provides an in-depth analysis of the U.S. meal replacements and OTC appetite suppressants market, examining the effects and strategic responses to GLP-1 drugs. This study is recognized as the most thorough investigation available globally regarding the U.S. meal replacements market.
The report encompasses various critical aspects including the dollar value and growth rate of the market, spanning from the early 1980s to 2024, with forecasts extending to 2025 and 2028. It details current market trends, significant company developments, and provides status reports for retail and multi-level marketing (MLM) meal replacements and weight loss supplements. The report also highlights major distribution channels and identifies key growth drivers, alongside analyzing the competition from GLP-1 drugs within the medical weight loss programs sector.
Key competitor profiles included in the report feature significant industry players such as Medifast, Herbalife, Slim-Fast (Glanbia), Simply Good Foods (Atkins Nutritionals), BeachBody, Visalis Life Sciences, Isagenix, Shaklee, AMWAY (Quixtar), and Nu-Skin. These profiles offer insights into strategic shifts and adaptations in response to evolving market conditions.
As the market navigates the challenges and opportunities posed by GLP-1 drugs, this report serves as an essential resource for stakeholders seeking to understand the dynamic landscape of the U.S. meal replacements industry. By examining the market's trajectory and competitive environment, industry actors can better strategize and capitalize on emerging trends.
Key Topics Covered:
Executive Overview
- Market definition and segments
- Size/growth of the commercial programs & products market: 2020-2028 forecast
- Discussion of the shift by dieters to GLP-1 drugs and medical programs
- Discussion of the pivot to virtual programs, impact & closures of retail weight loss centers
- Analysis of the explosion of the GLP-1 drugs market since 2022: major developments in the medical weight loss market
- Size/growth of medical weight loss programs: market segments
- Market Segment Status Reports & Outlooks (2025 & 2028 forecasts)
- Commercial weight loss centers
- Weight loss apps, virtual programs
- Retail & multi-level marketing meal replacements & appetite suppressants
- Diet Soft Drinks Market
- Artificial sweeteners market
- The Low-Calorie ("diet") & Low-Carb Foods Market
GLP-1 Weight Loss Drugs & Medical Programs: The Competition's Impact
- Summary & analysis of market share/revenues lost by commercial weight loss firms
- Major market developments & impacts on commercial programs since 2022
- Size & Structure of the medical weight Loss Market
- The GLP-1 weight loss drugs market: size, scope, possible headwinds, 2025 outlook, possibility of recession
- Medical Weight Loss Clinic Chains & Franchises: as competition for commercial programs
- Hospitals: type programs, as competition for commercial programs
- Independent physicians, as competition for commercial programs
The Retail Meal Replacements & Appetite Suppressants Market
- Definition/nature of meal replacements vs. over-the-counter (retail) weight loss supplements
- History/nature of mkt.- cyclical shifts from mid-1980s
- Market trends and key drivers
- Current Trends: Effects of the GLP-1 drugs boom
- Key distribution channels (MLM, retail, internet, healthcare pros)
- Scrutiny of OTC appetite suppressants
- Analysis of the market by Nutrition Business Journal
- 2023-2024 market performance: revenues of leading retail & MLM firms (Atkins, Herbalife, Slim-Fast, Premier Protein)
- 2025 & 2028 forecasts
- User demographics: no. and % of dieters using diet pills and meal replacements
- Why long-term outlook is stronger for meal replacements, preferred by MDs, MLMs, commercial chains, why retail diet pills mkt. still struggles, possible FTC actions
- List of the major meal replacement competitors
- NBJ estimates of diet pill & meal replacements $ and % sales, by distribution channels, discussion of multilevel firms (Advocare, Shaklee, Herbalife, Quixtar, Nu-Skin)
- Marketdata estimates of growth for diet pills & meal replacements 2025-2028 F, demand factors
Competitor Profiles
- (estd. or actual 2024 revenues, strategies, product lines, marketing)
- Medifast
- Slim-Fast (Glanbia)
- Herbalife
- Atkins (Simply Good Foods)
- Visalis Life Sciences
- Isagenix
- Shaklee
- AMWAY (Quixtar)
- Nu-Skin
- BODI (The Beachbody Co.)
Reference Directory of Weight Loss Information Sources
- Industry & government trade associations, journals, newsletters, magazines, consultants
For more information about this report visit https://www.researchandmarkets.com/r/retqrt
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
